Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

Research output: Contribution to journal › Research article › Contributed › peer-review

Contributors

  • Jeffrey A Cohen - , Barrow Neurological Institute (Author)
  • Robert A Bermel - , Barrow Neurological Institute (Author)
  • Cynthia I Grossman - , Biogen (Author)
  • Carrie M Hersh - , Lou Ruvo Center for Brain Health (LRCBH) (Author)
  • Megan Hyland - , University of Rochester (Author)
  • Ellen M Mowry - , Johns Hopkins University School of Medicine (Author)
  • Robert Naismith - , Washington University St. Louis (Author)
  • Maria L Naylor - , Biogen (Author)
  • Jacqueline Nicholas - , Riverside Methodist Hospital (Author)
  • Rajani Rajbhandar - , Biogen (Author)
  • Carol M Singh - , Biogen (Author)
  • Mar Tintorè - , Vall d'Hebron University Hospital (Author)
  • Ana Zabalza - , Vall d'Hebron University Hospital (Author)
  • Tjalf Ziemssen - , Department of Neurology, Multiple Sclerosis Center Dresden, Center of Clinical Neuroscience, University Hospital Carl Gustav Carus Dresden (Author)
  • James R Williams - , Biogen (Author)
  • Xavier Montalban - , Vall d'Hebron University Hospital (Author)

Abstract

BACKGROUND: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain.

METHODS: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response.

RESULTS: Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group.

CONCLUSION: Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.

Details

Original languageEnglish
Pages (from-to)1131-1137
Number of pages7
JournalMultiple Sclerosis Journal
Volume28
Issue number7
Publication statusPublished - Jun 2022
Peer-reviewedYes

External IDs

PubMedCentral PMC9131404
Scopus 85122656213

Keywords

Sustainable Development Goals

Keywords

  • Antibodies, Viral, COVID-19/prevention & control, COVID-19 Vaccines, Humans, Immunity, Immunoglobulin G, Multiple Sclerosis/drug therapy, SARS-CoV-2, Technology, Vaccination, Vaccines, Synthetic, mRNA Vaccines